NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

Nicely said Bright Boy. Yes, individualized, customized treatment is the advantage here and I think it will prove to be the core of a gold standard that may include other treatments to address the idiosyncratic pathologies of different cancer types and patient responses, but it will be, assuming things turn out as many of us expect, the way to craft an immune response exactly customized to all the antigens in that patient’s tumors. And let’s not forget that there will be two approaches including DCVax-L and DCVax Direct, and those will afford even more powerful ways to customize the immune response for that patient’s exact cancer. The mRNA approach is nothing like that, and takes the ideas back to static approaches that are intended to hit big and/or broad targets. They can add targets easily, after trials, once they learn perhaps that they did not get them all, but that is the same hit or miss approach that has been haunting cancer vaccines for a long time.